ADMA Biologics (ADMA) 10-K2016 FY Annual report

Filed: 24 Feb 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: absence, alleging, alter, andKedrion, andRodman, area, assert, asserting, assumption, awaiting, Barrett, batch, biocenter, BioManufacturing, Biopharma, bivigam, blended, blending, BPC, breakage, broker, Buyer, cap, chemical, Chemistry, cite, CIVACIR, Clarifying, CMC, commensurate, concurrence, conflict, consummate, consummated, consummation, conventional, convergence, convey, Council, deal, deferral, departure, deviation, disagreement, distinct, Earnest, emphasize, entirety, environmental, essential, exert, expert, FDASIA, feasibility, feedback, fiduciary, field, formulary, fundamental, fundraising, headcount, Home, horizon, imply, impossible, inactive, inappropriate, inclusive, indemnification, inflation, ingredient, injury, interfere, inThe, iscurrently, Kedrion, land, leverage, mandatory, Master, maximizing, microbial, misconduct, misleading, misrepresentation, monetary, mortgage, motivate, necessity, nonvoting, onset, organizational, output, outweigh, packaging, pari, Parkway, passed, passu, payor, PDMA, pendency, pharmacoeconomic, PIPE, pipeline, posted, PREA, pressure, privy, PSP, pure, rank, rapidly, regimen, reinterpreted, relaunch, Renshaw, resubmission, resubmit, Rodman, role, Seller, semiannually, Shire, signature, simplification, sixty, SK, Specimen, speech, standstill, subordinated, subpopulation, substantive, Syncytical, text, textual, thereunto, therewith, timeframe, timeline, traceable, truthful, undisclosed, unfair, unquantifiable, unregistered, unsecured, vertically, waiver, warranty, withheld

Removed: abstract, appoint, Baxter, CEO, Conference, confirm, construction, DC, deemed, dropped, eventual, finalize, finalized, heavily, hereof, identification, improved, judgment, lawful, lawfully, marketable, Mond, opening, oral, pertained, pioneer, procedural, protecting, ranging, ratify, refund, relationship, rented, resource, resubstitution, stability, titled, virtue

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ADMA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of ADMA Biologics, Inc., a Delaware corporation (the “Company”) on Form 10-K for the year ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Adam S. Grossman, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

February 24, 2017

/s/ Adam S. Grossman

Name:

Adam S. Grossman

Title:

President and Chief Executive Officer

(Principal Executive Officer)